TWI631127B - 巨環廣效抗生素 - Google Patents

巨環廣效抗生素 Download PDF

Info

Publication number
TWI631127B
TWI631127B TW102142527A TW102142527A TWI631127B TW I631127 B TWI631127 B TW I631127B TW 102142527 A TW102142527 A TW 102142527A TW 102142527 A TW102142527 A TW 102142527A TW I631127 B TWI631127 B TW I631127B
Authority
TW
Taiwan
Prior art keywords
formula
compound
alkyl
another embodiment
group
Prior art date
Application number
TW102142527A
Other languages
English (en)
Chinese (zh)
Other versions
TW201434848A (zh
Inventor
塔克 克倫 羅伯茲
彼德 安德魯 史密斯
羅伯特I 希古奇
大衛 坎貝爾
普拉蘇納 帕拉賽利
Original Assignee
Rqx製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rqx製藥公司 filed Critical Rqx製藥公司
Publication of TW201434848A publication Critical patent/TW201434848A/zh
Application granted granted Critical
Publication of TWI631127B publication Critical patent/TWI631127B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW102142527A 2012-11-21 2013-11-21 巨環廣效抗生素 TWI631127B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261729249P 2012-11-21 2012-11-21
US201261729253P 2012-11-21 2012-11-21
US61/729,253 2012-11-21
US61/729,249 2012-11-21

Publications (2)

Publication Number Publication Date
TW201434848A TW201434848A (zh) 2014-09-16
TWI631127B true TWI631127B (zh) 2018-08-01

Family

ID=50728492

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102142527A TWI631127B (zh) 2012-11-21 2013-11-21 巨環廣效抗生素

Country Status (12)

Country Link
US (1) US9309285B2 (enExample)
EP (1) EP2922829B1 (enExample)
JP (2) JP6437443B2 (enExample)
KR (1) KR20150088292A (enExample)
CN (1) CN104903302B (enExample)
AR (1) AR093581A1 (enExample)
BR (1) BR112015011697A2 (enExample)
CA (1) CA2892027A1 (enExample)
EA (1) EA201590871A1 (enExample)
MX (1) MX2015006340A (enExample)
TW (1) TWI631127B (enExample)
WO (1) WO2014081886A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
BR112015021036A2 (pt) 2013-03-15 2017-10-10 Univ Pennsylvania composições e métodos para tratar mps1
KR20170027721A (ko) 2014-05-20 2017-03-10 알큐엑스 파마슈티컬스, 인크. 마크로시클릭 광범위 항생제
PL3289355T3 (pl) * 2015-04-30 2025-11-24 Idexx Laboratories, Inc. Sposoby wykrywania chorób nerek
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
KR20180109858A (ko) * 2015-11-20 2018-10-08 알큐엑스 파마슈티컬스, 인크. 마크로시클릭 광범위 항생제
TWI725075B (zh) * 2015-11-20 2021-04-21 美商Rqx製藥公司 巨環廣效抗生素
UA126027C2 (uk) * 2017-02-15 2022-08-03 АрКьюЕкс ФАРМАСЬЮТІКЛС, ІНК. Макроциклічні антибіотики широкого спектра
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
IL288294B (en) * 2019-05-28 2022-09-01 Hoffmann La Roche A broad-spectrum macrocyclic antibiotic

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025350A (en) * 1997-08-06 2000-02-15 Pfizer Inc. C-4" substituted macrolide antibiotics
US20070099885A1 (en) * 2003-12-16 2007-05-03 Aicuris Gmbh & Co. Kg Antibacterial macrocycles with substituted biphenyl
WO2011112441A1 (en) * 2010-03-09 2011-09-15 Merck Sharp & Dohme Corp. Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials
WO2012036907A2 (en) * 2010-09-15 2012-03-22 Romesberg Floyd E Broad spectrum antibiotic arylomycin analogs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
US6660832B1 (en) * 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
US6951840B2 (en) * 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
DE10226921A1 (de) * 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
JP2007536200A (ja) 2003-07-17 2007-12-13 ミジェニックス インコーポレイテッド リポペプチド抗生物質誘導体の組成物およびその使用方法
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
DE102005014247A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen VI
WO2011120071A1 (en) 2010-04-01 2011-10-06 The University Of Queensland Oxytocin peptide analogues
WO2012166665A2 (en) 2011-05-27 2012-12-06 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
KR20140140580A (ko) 2012-03-14 2014-12-09 더 스크립스 리서치 인스티튜트 광범위 항생제 아릴로마이신 유사체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025350A (en) * 1997-08-06 2000-02-15 Pfizer Inc. C-4" substituted macrolide antibiotics
US20070099885A1 (en) * 2003-12-16 2007-05-03 Aicuris Gmbh & Co. Kg Antibacterial macrocycles with substituted biphenyl
WO2011112441A1 (en) * 2010-03-09 2011-09-15 Merck Sharp & Dohme Corp. Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials
WO2012036907A2 (en) * 2010-09-15 2012-03-22 Romesberg Floyd E Broad spectrum antibiotic arylomycin analogs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Holtzel et al, Journal of Antibiotics, 2002, 55(6), p571-577
Schimana et al, Journal of Antibiotics, 2002, 55(6), p565-570
Schimana et al, Journal of Antibiotics, 2002, 55(6), p565-570 Holtzel et al, Journal of Antibiotics, 2002, 55(6), p571-577 *

Also Published As

Publication number Publication date
JP6662960B2 (ja) 2020-03-11
TW201434848A (zh) 2014-09-16
US9309285B2 (en) 2016-04-12
JP2016501864A (ja) 2016-01-21
KR20150088292A (ko) 2015-07-31
EP2922829B1 (en) 2021-08-11
CA2892027A1 (en) 2014-05-30
AR093581A1 (es) 2015-06-10
WO2014081886A1 (en) 2014-05-30
EP2922829A4 (en) 2016-11-02
BR112015011697A2 (pt) 2017-07-11
JP6437443B2 (ja) 2018-12-12
CN104903302A (zh) 2015-09-09
EP2922829A1 (en) 2015-09-30
JP2018184435A (ja) 2018-11-22
CN104903302B (zh) 2019-03-29
US20140142029A1 (en) 2014-05-22
MX2015006340A (es) 2015-09-07
EA201590871A1 (ru) 2015-11-30

Similar Documents

Publication Publication Date Title
JP7148652B2 (ja) 大環状広域スペクトル抗生物質
JP6662960B2 (ja) 大環状広域抗生物質
CN108884058B (zh) 大环广谱抗生素
TWI642684B (zh) 廣效性抗生素
TWI601746B (zh) 線型肽抗生素
CN109219596B (zh) 大环广谱抗生素
CN110520413A (zh) 大环广谱抗生素
CN105636978A (zh) 线性肽抗生素
US10501493B2 (en) Broad spectrum antibiotics
HK40002868A (en) Macrocyclic broad spectrum antibiotics
HK40002868B (en) Macrocyclic broad spectrum antibiotics
HK40000284A (en) Macrocyclic broad spectrum antibiotics
HK40000284B (en) Macrocyclic broad spectrum antibiotics

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees